背景:既往的临床研究显示:通过抑制血管内皮生长因子和表皮生长因子受体结合途径可以治疗胰腺癌。根据第一阶段4种药物的疗效和毒性的剂量研究,利用吉西他滨和卡培他滨联合贝伐单抗和埃罗替尼治疗晚期胰腺癌患者,从而对4种药物作出进一步评估。方法:局部晚期或者远处转移的胰腺 BACKGROUND: Previous clinical studies have shown that pancreatic cancer can be treated by inhibiting the binding of vascular endothelial growth factor and epidermal growth factor receptors. Based on the dose and efficacy studies of the four drugs in the first phase, the use of gemcitabine and capecitabine in combination with bevacizumab and erlotinib for the treatment of patients with advanced pancreatic cancer was used to further evaluate the four drugs. Methods: Pancreas with locally advanced or distant metastasis